Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20170216
    Release date: 30 May 2017

    Promoter – Financial Intermediary

    CELLNOVO GROUP SA

    Location

    Description

    Investment in Cellnovo's facilities in order to develop its innovative connected all-in-one diabetes management system focused primarily on type 1 diabetes patients

    Objectives

    The aim of the project is to scale up production of Cellnovo's novel micro-pump for type 1 diabetes patients and support related capital expenditure for products it plans to bring to the market in the future.

    Sector(s)

    • Services - Professional, scientific and technical activities

    Proposed EIB finance (Approximate amount)

    EUR 20 million

    Total cost (Approximate amount)

    EUR 41 million

    Environmental aspects

    All project activities are expected to be carried out in existing facilities without changing the already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending the EIA Directive 2011/92/EU.

    Procurement

    The promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions.

    Status

    Signed - 7/07/2017

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    France Services